{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:10:21Z","timestamp":1756293021903,"version":"3.44.0"},"reference-count":16,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,6,24]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>A male in his early 20s presented with severe skeletal pain and diffuse osteosclerosis caused by extensive osteoblastic skeletal metastases from a Central Nervous System (CNS) Embryonal Tumour (WHO Grade 4), leading to hypocalcemia and hypophosphatemia. Biochemical evaluation revealed elevated parathyroid hormone and high vitamin D levels; imaging confirmed widespread osteoblastic metastases. Low urinary fractional excretion of calcium suggested high uptake into the bone. The biochemical profile resembled vitamin D resistance but represents a distinct pathophysiological entity. Pancytopenia due to marrow infiltration precluded chemotherapy and radiotherapy, prompting a focus on supportive and palliative care. Management included oral calcium and phosphorus supplementation alongside symptom control and psychosocial support. This case illustrates the rare metabolic complication of hypocalcemia and hypophosphatemia secondary to osteoblastic metastases in a CNS malignancy. It emphasises recognising such metabolic derangements and adopting a multidisciplinary approach to optimise management and improve patient quality of life.<\/jats:p>","DOI":"10.1136\/bcr-2025-264881","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T17:50:23Z","timestamp":1751910623000},"page":"e264881","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Hypocalcemia and hypophosphatemia due to osteoblastic metastases from central nervous system embryonal tumour."],"prefix":"10.1136","volume":"18","author":[{"given":"Rajesh Yadav","family":"Borra","sequence":"first","affiliation":[{"name":"Endocrinology and Metabolism, All India Institute of Medical Sciences Mangalagiri, Mangalagiri, Andhra Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0833-6105","authenticated-orcid":false,"given":"Venkata Sai Krishna Reddy","family":"Nareddy","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism, All India Institute of Medical Sciences Mangalagiri, Mangalagiri, Andhra Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Chavali","sequence":"additional","affiliation":[{"name":"Pathology, Manipal Hospitals Guntur Tadepalli, Tadepalli Guntur, Andhra Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raza Shabuddin","family":"Gouri","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism, All India Institute of Medical Sciences Mangalagiri, Mangalagiri, Andhra Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"2025082703484864000_18.7.e264881.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra070553"},{"key":"2025082703484864000_18.7.e264881.2","doi-asserted-by":"crossref","first-page":"V105","DOI":"10.1359\/jbmr.07s210","article-title":"Vitamin D-resistant diseases","volume":"22 Suppl 2","author":"Liberman","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2025082703484864000_18.7.e264881.3","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2018-101065"},{"key":"2025082703484864000_18.7.e264881.4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0528"},{"key":"2025082703484864000_18.7.e264881.5","doi-asserted-by":"crossref","unstructured":"Seker A , Durmus NS . Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia. Egypt J Intern Med 2025;37. doi:10.1186\/s43162-025-00406-z","DOI":"10.1186\/s43162-025-00406-z"},{"key":"2025082703484864000_18.7.e264881.6","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMcp2113128","article-title":"Cancer-Associated Hypercalcemia","volume":"386","author":"Guise","year":"2022","journal-title":"N Engl J Med"},{"key":"2025082703484864000_18.7.e264881.7","doi-asserted-by":"crossref","DOI":"10.3390\/cells13121051","article-title":"Hypercalcemia in Cancer: Causes, Effects, and Treatment Strategies","volume":"13","author":"Bartkiewicz","year":"2024","journal-title":"Cells"},{"key":"2025082703484864000_18.7.e264881.8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.0954-6820.1986.tb02745.x","article-title":"A hospital survey of hypocalcemia in patients with malignant disease","volume":"220","author":"Blomqvist","year":"1986","journal-title":"Acta Med Scand"},{"key":"2025082703484864000_18.7.e264881.9","doi-asserted-by":"crossref","unstructured":"Zeng W , Swee DS . n.d. Severe and refractory hypocalcaemia secondary to osteoblastic bone metastases in bladder signet ring carcinoma: A case report and literature review. Medicine (Abingdon) 101:e29731. doi:10.1097\/MD.0000000000029731","DOI":"10.1097\/MD.0000000000029731"},{"key":"2025082703484864000_18.7.e264881.10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s43162-025-00406-z","article-title":"Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia","volume":"37","author":"Seker","year":"2025","journal-title":"Egypt J Intern Med"},{"key":"2025082703484864000_18.7.e264881.11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM196001282620404","article-title":"Hypocalcemia in the presence of osteoblastic metastases","volume":"262","author":"SACKNER","year":"1960","journal-title":"N Engl J Med"},{"key":"2025082703484864000_18.7.e264881.12","doi-asserted-by":"crossref","first-page":"bcr","DOI":"10.1136\/bcr-2018-225039","article-title":"Hungry bone syndrome secondary to prostate cancer successfully treated with radium therapy","volume":"2018","author":"Garla","year":"2018","journal-title":"BMJ Case Rep"},{"key":"2025082703484864000_18.7.e264881.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc867"},{"key":"2025082703484864000_18.7.e264881.14","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/cncr.24896","article-title":"Pathogenesis of osteoblastic bone metastases from prostate cancer","volume":"116","author":"Ibrahim","year":"2010","journal-title":"Cancer"},{"key":"2025082703484864000_18.7.e264881.15","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s11914-018-0480-6","article-title":"Osteoblastic Factors in Prostate Cancer Bone Metastasis","volume":"16","author":"Lin","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"2025082703484864000_18.7.e264881.16","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-013-9625-2"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-264881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:48:58Z","timestamp":1756291738000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-264881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,7]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bcr-2025-264881"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-264881","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}